What Has Been The Evolution of the Self Administered Parenteral Market in Recent Years?
The self administered parenteral market has seen considerable growth due to a variety of factors.
• In recent years, the market size for self-administrated parenteral products has increased robustly. A rise from $24.57 billion in 2024 to $26.04 billion in 2025 is expected, representing a compound annual growth rate (CAGR) of 6.0%.
The expansion during the historical period can be traced back to factors like the escalating prevalence of chronic diseases, the aging population, government policies, initiatives aimed at patient education and support programs, and an increase in cases of bone ailments.
What Are the Future Growth Projections for the Self Administered Parenteral Market?
The self administered parenteral market is expected to maintain its strong growth trajectory in upcoming years.
• The market for self-administered parenteral treatments is predicted to see consistent expansion in the coming years, reaching a worth of $31.18 billion in 2029, with a compound annual growth rate (CAGR) of 4.6%.
This growth during the projected period can be ascribed to factors such as rising patient inclination towards home healthcare, telemedicine, remote patient surveillance, patient instruction and support initiatives, and the expansion of personalized medicine. Key trends during this period comprise the incorporation of digital health solutions, personalized drug delivery systems, the onset of targeted therapies, and advancements in biologics.
What Are The Core Factors Supporting Growth In The Self Administered Parenteral Market?
The escalation in chronic disease cases is anticipated to fuel the expansion of the self-administered parenteral market. Chronic diseases are enduring health problems that typically advance sluggishly over time, often necessitating continuous management and therapy. Self-administered parenteral products play a crucial role in managing chronic diseases, facilitating treatment management independently and potentially enhancing adherence compared to oral medication. For example, in January 2023, the National Institutes of Health, a U.S. government agency, projected that the number of individuals aged 50 and above with at least one chronic disease would surge by 99.5% from 71.522 million in 2020 to 142.66 million by 2050. Hence, the increasing prevalence of chronic diseases is propelling the expansion of the self-administered parenteral market.
What Are The Major Segments Within The Global Self Administered Parenteral Market?
The self-administered parenteral market covered in this report is segmented –
1) By Product: Pre-Filled Syringes, Autoinjectors, Pen Injectors, Other Products
2) By Usage: Disposable, Reusable
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Home Healthcare Providers, Specialty Clinics, Other Distribution Channels
4) By Application: Cardiovascular Diseases, Diabetes, Osteoporosis, Pain Management, Hormone Replacement, Other Applications
Subsegments:
1) By Pre-Filled Syringes: Glass Pre-Filled Syringes, Plastic Pre-Filled Syringes
2) By Autoinjectors: Disposable Autoinjectors, Reusable Autoinjectors
3) By Pen Injectors: Insulin Pen Injectors, Growth Hormone Pen Injectors, Other Pen Injectors
4) By Other Products: Infusion Pumps, Needle-Free Injectors, Combination Devices
Pre-Book The Self Administered Parenteral Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are Emerging Trends Reshaping The Dynamics Of The Self Administered Parenteral Market?
Leading businesses in the self-administered parenteral market, such as Coherus BioSciences Inc., are seeking to evolve with innovative product developments like the UDENYCA autoinjector, aiming to give more options and power to the patients, thereby enhancing the accessibility of the treatments. An autoinjector, by design, is a medical instrument developed to deliver a specific one-time drug dose, and the administration of the same is instantly and reliably initiated when pushed against the skin. To put it in context, in May 2023, Coherus BioSciences Inc, a biotech firm based in the US, premiered the UDENYCA autoinjector, a type of self-administered parenteral drug in the United States. The UDENYCA Autoinjector is a single-use, prefilled device allowing an alternative administering method for pegfilgrastim. The design is user-friendly, permitting reliable, and immediate delivery of the full pegfilgrastim dose upon push-on-skin activation. The autoinjector boasts several advantageous features leading to successful delivery, such as rapid dosing, a straightforward design, dual coverage, flexibility for home or office use, and reduced risk of febrile neutropenia.
Who Are the Key Players In The Self Administered Parenteral Market?
Major companies operating in the self-administered parenteral market report are:
• Pfizer Inc.
• Johnson & Johnson
• Merck & Co. Inc.
• Sanofi S.A.
• AstraZeneca PLC
• Roche Holding AG
• Eli Lilly and Company
• Novo Nordisk A/S
• Becton
• Dickinson and Company
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Terumo Corporation
• Catalent Inc.
• Dexcom Inc.
• West Pharmaceutical Services Inc.
• Gerresheimer AG
• Biocon Limited
• Insulet Corporation
• Halozyme Therapeutics Inc.
• Ypsomed AG
• Antares Pharma Inc.
• SHL Medical AG
• Owen Mumford Ltd.
• Novartis AG
• Kaleo Inc.
• Haselmeier AG
• Bespak (A Consort Medical Company)
• Senseonics Holdings Inc.
• ScPharmaceuticals Inc.
• Fresenius Kabi AG
What Is The Most Dominant Region In The Self Administered Parenteral Market?
North America was the largest region in the self-administered parenteral market in 2024. The regions covered in the self-administered parenteral market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
